Rallybio Corporation announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31stCongress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.805 USD | -2.96% | -1.13% | -24.30% |
May. 15 | JPMorgan Downgrades Rallybio to Neutral From Overweight | MT |
May. 09 | Rallybio Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.30% | 77.1M | |
+32.42% | 50.85B | |
+0.12% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.73% | 26.11B | |
-22.22% | 19.13B | |
+8.57% | 13.05B | |
+27.38% | 12.16B | |
+24.38% | 12.08B |
- Stock Market
- Equities
- RLYB Stock
- News Rallybio Corporation
- Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study